Next big delta in pharma to come from biosimilars: Nithya Balasubramanian

“For Aurobindo Pharma, our official rating is market performance. We do not recommend it from a long-term perspective. It is only a tactical recommendation for the next couple of quarters for the reasons that you just read out. In the case of Gland Pharma, Bernstein sees operational leverage.”